下一代疗法比拼升级Infigratinib并非唯一挑战Vosoritide的选手，在ACH治疗赛道，多款下一代疗法正加速推进，从周剂注射到高选择性靶向，行业的研发比拼正不断升级，Vosoritide的垄断时代已进入倒计时。
Explore our full range of subscriptions.For individuals
，更多细节参见快连下载安装
The parameters for onboarding new developers are now clearly defined, with a low barrier to entry focused on competence with the tools. These tests are called showcases.
Readers respond to an interview with Beth Gardiner on how the oil industry is pumping billions more into plastics
Nicola Ellis is currently exhibiting her work at HOME in Manchester